Glaucocalyxin A

• CAT Number: I017708
• CAS Number: 79498-31-0
• Molecular Formula: C₂₀H₂₈O₄
• Molecular Weight: 332.43
• Purity: ≥95%
• Target: Apoptosis
• IUPAC Name: (1R,2R,4S,9R,10S,13S,16R)-2,16-dihydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-6,15-dione
• InChI: InChI=1S/C20H28O4/c1-10-11-5-6-12-19(4)8-7-14(21)18(2,3)13(19)9-15(22)20(12,16(10)23)17(11)24/h11-13,15,17,22,24H,1,5-9H2,2-4H3/t11-,12-,13+,15+,17+,19-,20-/m0/s1
• InChIKey: UCDVIBNDYLUWFP-MJTHGBBVSA-N
• SMILES: C[C@@]12CCC(=O)C([C@H]1C[C@H]([C@]34[C@H]2CC[C@H]([C@H]3O)C(=C)C4=O)O)(C)C

Glaucocalyxin A (Cat No.:I017708) is a natural diterpenoid compound isolated from the Chinese herb Rabdosia japonica. It possesses various pharmacological activities and has shown potential as an anticancer agent. Glaucocalyxin A exhibits cytotoxic effects against a wide range of cancer cell lines, including lung, breast, prostate, and colon cancers. It induces cell cycle arrest and apoptosis by regulating multiple signaling pathways, including the PI3K/AKT/mTOR, NF-κB, and MAPK pathways. Glaucocalyxin A also displays anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines. Furthermore, it exhibits anti-angiogenic activity by suppressing the formation of new blood vessels. These diverse biological activities make Glaucocalyxin A an interesting compound for further investigation as a potential therapeutic agent in cancer treatment and other diseases.

Reference

[1]. Zhu J, et al. Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nucleartranslocation via regulating PI3K/Akt pathway. Cell Death Dis. 2018 Jun 13;9(6):708.